Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues.

ABSTRACT:

Background

Optimal cytoreduction to no residual disease (R0) correlates with improved disease outcome for high-grade serous ovarian cancer (HGSOC) patients. Treatment of HGSOC patients with neoadjuvant chemotherapy, however, may select for tumor cells harboring alterations in hallmark cancer pathways including metastatic potential. This study assessed this hypothesis by performing proteomic analysis of matched, chemotherapy naïve and neoadjuvant chemotherapy (NACT)-treated HGSOC tumors obtained from patients who had suboptimal (R1, n = 6) versus optimal (R0, n = 14) debulking at interval debulking surgery (IDS).

Methods

Tumor epithelium was harvested by laser microdissection from formalin-fixed, paraffin-embedded tissues from matched, pre- and post-NACT treated tumors for tw

SUBMITTER: Penick ER 

PROVIDER: S-EPMC9531351 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature